BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/28/2020 10:08:51 AM | Browse: 1047 | Download: 1932
 |
Received |
|
2019-06-22 08:09 |
|
Peer-Review Started |
|
2019-06-24 08:07 |
|
First Decision by Editorial Office Director |
|
2019-08-27 23:35 |
|
Return for Revision |
|
2019-08-29 01:23 |
|
Revised |
|
2019-09-26 05:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-10-18 10:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-10-19 22:18 |
|
Articles in Press |
|
2019-10-19 22:18 |
|
Edit the Manuscript by Language Editor |
|
2019-11-29 22:31 |
|
Typeset the Manuscript |
|
2019-12-14 07:14 |
|
Publish the Manuscript Online |
|
2020-02-28 10:08 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Tao Fu, Jing-Jing Tian, Ying-Ying Xu, Jia-Xin Fu, Shao-Ling Nie, Yan-Yan Tang, Ping Chen and Liang Zong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Liang Zong, PhD, Doctor, Doctor, Professor, Research Associate, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225001, Jiangsu Province, China. 250537471@qq.com |
| Key Words |
Capecitabine plus oxaliplatin chemotherapy; Colon cancer; Meta-analysis; Long-term effect; ; |
| Core Tip |
Many clinical studies for the long-term survival or efficacy of capecitabine plus oxaliplatin (XELOX) in colon cancer have already been studied, but its clinical benefit is controversial. The long-term efficacy of XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer was evaluated. By searching the PubMed, Embase and Cochrane, a total of 12 randomized controlled trials involving 6698 stage III colon cancer cases were included. Our findings pointed that XELOX regimen showed a better OS and a better disease-free survival. The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery. |
| Publish Date |
2020-02-28 10:08 |
| Citation |
Fu HT, Tian JJ, Xu YY, Fu JX, Nie SL, Tang YY, Chen P, Zong L. Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis. World J Meta-anal 2020; 8(1): 27-40 |
| URL |
https://www.wjgnet.com/2308-3840/full/v8/i1/27.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v8.i1.27 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
